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ABSTRACT
AIM: The risk factors for hepatocellular carcinoma (HCC) development in chronic 
hepatitis B (CHB) patients with undetectable serum HBV DNA under nucleos(t)ide 
analogue (NA) therapy are not well defined. We aimed to examine the relationship 
between Wisteria floribunda agglutinin-positive human Mac-2 binding protein (WFA+-
M2BP) and HCC development in these patients. 
Results: There was a significant difference in the median levels of pre-treatment 
WFA+-M2BP between the HCC and control groups (0.67 vs 0.41 COI, respectively, 
p < 0.001). Among patients with cirrhosis, the median level of WFA+-M2BP was higher 
in HCC group than in control group (0.74 vs 0.47 COI, respectively, p = 0.014). Among 
patients without cirrhosis, the median level of WFA+-M2BP of HCC group was also 
higher (0.48 vs 0.28 COI, respectively, p = 0.002). With a cutoff value of 0.69, the 
AUROC of pre-treatment WFA+-M2BP to predict HCC development for the whole cohort 
was 0.70. With cutoff values of 0.69 and 0.34, the AUROCs to predict HCC were 0.67 
and 0.77 for patients with and without cirrhosis, respectively. 
Materials and Methods: Fifty-seven NA-treated patients with undetectable HBV DNA 
who developed HCC were compared with 57 controls (matched with demographics and 
treatment duration). WFA+-M2BP levels were measured, and expressed as cutoff index 
(COI). Subgroup analyses were also performed in patients with and without cirrhosis. 
Conclusions: A higher pre-treatment WFA+-M2BP level was associated with an 
increased risk of HCC development in patients with undetectable HBV DNA under NA 
therapy. Further longitudinal studies are required to examine the role of WFA+-M2BP 
as an accessory risk marker for HCC development. 
INTRODUCTION
Hepatitis B virus (HBV) infection is one of the 
commonest chronic infections, affecting 248 million people 
worldwide [1], with more than 1 million people dying 
from HBV-related diseases annually [2]. Chronic hepatitis 
B (CHB) infection can lead to various adverse outcomes, 
including hepatitis flares, cirrhosis and hepatocellular 
carcinoma (HCC) [3]. Among various risk factors for HCC 
development, cirrhosis and high serum HBV DNA levels 
(≥ 2,000 IU/mL) are the major ones [3, 4]. 
Chronic hepatitis results in regeneration and 
cirrhosis. The risk of HCC is significantly increased 
in case of cirrhosis, due to the activation of oncogenes, 
overexpression of growth factors and inactivation of 
tumor suppressor genes [5]. Therefore, it is of paramount 
importance in assessing the severity of liver fibrosis and 
cirrhosis, in an accurate and timely manner. This helps 
in prognostication and in turns affects management like 
antiviral treatment initiation, endoscopic screening for 
varices and screening for HCC. Although liver biopsy 
is a gold standard, it is an invasive procedure associated 
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with various complications which occasionally can be 
life-threatening [6]. Currently available non-invasive 
methods include direct and indirect serum markers, 
transient elastography, and magnetic resonance (MR) 
elastography. However, each of these investigatory 
modalities is associated with certain disadvantages [7]. 
Recently, a lectin-antibody sandwich immunoassay has 
been developed for measuring a novel serum glyco-marker 
for assessing liver fibrosis. This serum marker is known as 
the Wisteria floribunda agglutinin positive Mac-2 binding 
protein (WFA+-M2BP) [8, 9]. The test has the advantages 
of being simple, rapid and noninvasive. 
M2BP has a special characteristic that changes its 
sugar chain structure following the progression of hepatic 
fibrosis. WFA is a lectin used to recognize the altered 
glycan parts of the M2BP secreted from the diseased cells 
[8]. WFA+-M2BP has been proven to be a useful marker in 
quantification of fibrosis in patients with hepatitis [8, 10]. 
The diagnostic performance of this test is superior to many 
currently available surrogate markers of fibrosis including 
APRI (AST to platelet ratio index), hyaluronic acid and 
type IV collagen peptide [10]. Clinical applicability of this 
marker in fibrosis has been studied in patients with viral 
hepatitis [11–14]. 
Apart from determining the degree of fibrosis, 
WFA+-M2BP has been found to be a useful surrogate 
marker for predicting HCC development in hepatitis 
C virus (HCV) patients [15, 16]. Recently, a few 
retrospective studies also demonstrated the potential role 
of this marker in predicting development of HCC in CHB 
patients [11, 12, 17]. However, these studies involved a 
heterogeneous group of patients who were both treatment-
naïve and treatment-experienced (with either interferon or 
NA therapy). Although several existing models can predict 
HCC development in treatment-naïve patients, there are no 
satisfactory tests to predict HCC in patients under treatment 
[18]. With potent nucleos(t)ide analogues (entecavir and 
tenofovir), majority of CHB patients are able to achieve 
profound viral suppression with undetectable serum HBV 
DNA level. However, antiviral therapy can only reduce but 
not eliminate the risk of HCC [19]. 
Therefore, our study aimed to investigate the 
association of WFA+-M2BP with HCC development in 
patients with undetectable HBV DNA by NA therapy. 
RESULTS 
Patient characteristics 
The demographics of the study population (57 HCC 
patients and 57 controls) are illustrated in Table 1. There 
were no significant differences between the two groups in 
terms of age, gender, HBeAg status, cirrhosis status, serum 
HBV DNA level and duration of therapy. The median age 
of the HCC group was similar to that of the control group 
(61.4 and 61.1 years, respectively, p = 0.764). Eighty-four 
percent of the cohort were male, 98.2% were HBeAg-
negative, and 59.6% had cirrhosis. The median duration of 
NA therapy was also comparable between the two groups 
(3.2 and 3.6 years, respectively, p = 0.626). There were 
no significant differences in other variables, except for a 
higher median AFP (11 vs 3 ng/mL, p < 0.001) and ALT 
level (29 vs 23 U/L, p = 0.009) in the HCC group. 
At the time of commencement of NA therapy, both 
groups did not have a significant difference in the median 
ALT levels (99 U/L [IQR: 51–192] and 95 U/L [IQR: 55–
153] in HCC and control groups, respectively). With regard 
to the fibrosis status, there was no significant difference 
in the proportions of patients with significant fibrosis 
(FIB-4 > 1.45) between the HCC and control groups, 
both before treatment (89.5% vs 86.0%, respectively, 
p = 0.326) and after treatment (82.5% vs 75.4%, 
respectively, p = 0.358). 
Table 2 shows the demographics of patients stratified 
according to the status of cirrhosis. The proportions of 
patients receiving different NA therapies are listed in Table 3.
Correlation between pre-treatment WFA+-M2BP 
and other variables
Pre-treatment WFA+-M2BP had a weak positive 
correlation with age (r = 0.21, p = 0.027) and pre-
treatment HBV DNA level (r = 0.19, p = 0.050). A positive 
correlation also existed between WFA+-M2BP and FIB-4 
(r = 0.63, p < 0.001), bilirubin (r =  0.43, p < 0.001) 
and INR (r = 0.21, p = 0.027), while there were negative 
correlations with albumin (r = –0.49, p < 0.001) and 
platelet (r = –0.32, p = 0.001). WFA+-M2BP did not 
have correlation with ALT (r = 0.12, p = 0.203) and AFP 
(r = –0.001, p = 0.995). These results indicate a positive 
relationship between WFA+-M2BP and adverse liver 
function. 
Comparison of pre- and post-treatment WFA+-
M2BP levels between the HCC and control 
groups
Figure 1 shows the pre-treatment and post-treatment 
WFA+-M2BP levels between the HCC and control groups 
for the whole cohort and also according to cirrhosis status. 
The median level of pre-treatment WFA+-M2BP was 
significantly higher in the HCC than the control groups 
(0.67 COI, IQR: 0.40–1.02 vs 0.41 COI, IQR: 0.28–0.56, 
respectively; p < 0.001). Among patients with cirrhosis 
(n = 68), the median level of WFA+-M2BP remained 
significantly higher in the HCC than the control groups 
(0.74 COI, IQR: 0.43–1.02 vs 0.47 COI, IQR: 0.40–0.68, 
respectively; p = 0.014). Among patients without cirrhosis 
(n = 46), there was also a significant difference in the 
median levels of WFA+-M2BP between the HCC and 
control groups (0.48 COI, IQR: 0.35–0.92 vs 0.28 COI, 
IQR: 0.23–0.44, respectively; p = 0.002). 
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However, there was no significant difference in the 
median levels of post-treatment WFA+-M2BP between 
the HCC and control groups (0.65 COI, IQR: 044–0.97 
vs 0.54 COI, IQR: 0.41–0.82, respectively; p = 0.161). 
Subgroup analysis also did not reveal any significant 
associations (cirrhosis-positive patients: 0.66 COI, IQR: 
0.45–1.05 in HCC group vs 0.69 COI, IQR: 0.47–0.85 in 
control group, p = 0.654; cirrhosis-negative patients: 0.65 
COI, IQR: 0.44–0.81 in HCC group vs 0.45 COI, IQR 
0.33–0.62 in control group, p = 0.077).
The role of pre-treatment WFA+-M2BP in 
predicting HCC development 
By maximizing the Youden’s index, the cutoff 
values of pre-treatment WFA+-M2BP to predict HCC 
development in CHB patients who achieved undetectable 
serum HBV DNA while on NA therapy were 0.69, 0.69 
and 0.34 for the whole cohort, cirrhotic patients and 
non-cirrhotic patients, respectively. The corresponding 
AUROC was 0.70 (95% CI: 0.61–0.80) (Figure 2A), 
0.67 (95% CI: 0.54–0.80) (Figure 2B) and 0.77 (95% 
CI: 0.63–0.91) (Figure 2C), respectively. Table 4 shows 
the predictive accuracies of pre-treatment WFA+-M2BP in 
different groups of patients. For the whole cohort, this test 
has a high specificity in identifying patients without HCC 
development (84%). Among patients without cirrhosis, 
with a lower cutoff value, this test has a high sensitivity 
in identifying patients with future HCC development 
(83%). In the whole study cohort, compared with patients 
with a pre-treatment WFA+-M2BP level < 0.69 COI, the 
OR of HCC development in patients with pre-treatment 
WFA+-M2BP ≥ 0.69 COI was 4.80 (95% CI: 1.83–12.58; 
p = 0.001). 
Comparison of pre-treatment HBV DNA levels 
between the HCC and control groups
There existed no significant difference in the median 
levels of pre-treatment HBV DNA between the HCC and 
control groups (6.5 and 6.0 log
10
IU/mL, respectively, 
p = 0.092). Univariate analysis in terms of categorical 
Table 1: Demographics of 114 CHB patients
HCC
(n = 57)
Non-HCC
(n = 57) p value
Age#, years 61.4
(55.9–62.0)
61.1
(56.9–66.3) 0.764
Male#, n (%) 48(84.2%)
48
(84.2%) n.a.
HBeAg-negative#, n (%) 56(98.2%)
56
(98.2%) n.a.
Cirrhosis#, n (%) 34(59.6%)
34
(59.6%) n.a.
Albumin, g/L 44(41–46)
44
(42–46) 0.813
Bilirubin, umol/L 12(8–15)
11
(8–17) 0.370
ALT, U/L 29
(20–38)
23
(20–28)
0.009
Platelet, x 10 ^9/L 163
(115–203)
168
(137–215) 0.151
INR 1.1(1–1.1)
1.1
(1–1.1) 0.865
AFP, ng/mL 11(5–32)
3
(2–4) < 0.001
Undetectable DNA#, n (%) 57
(100%)
57
(100%)
n.a.
Duration of therapy#, years 3.2
(2.0–5.0)
3.6
(2.2–5.1) 0.626
Continuous variables expressed as median (interquartile range).
CHB, chronic hepatitis B virus; HCC, hepatocellular carcinoma; ALT, alanine aminotransferase; INR, international 
normalised ratio; AFP, alpha-fetal protein.
#Matched variables.
n.a., p-value not applicable as these were matched categorical variables.
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variable (with two cutoff values of either 2,000 IU/mL or 
20,000 IU/mL) did not show any significant association 
between pre-treatment HBV DNA level and HCC 
development (p = 0.706 and 0.808, respectively).
 WFA+-M2BP levels in patients with cirrhosis  
Among the controls who did not have HCC (n = 57), 
the median level of pre-treatment WFA+-M2BP was 
significantly higher in patients with cirrhosis (0.47 COI; 
IQR: 0.40–0.68) than that of patients without cirrhosis 
(0.28 COI; IQR: 0.23–0.44) (p = 0.014). 
Similarly, there was a significant difference in the 
median level of post-treatment WFA+-M2BP between 
the two subgroups (cirrhosis-positive patients: 0.69 COI, 
IQR: 0.47–0.85 vs cirrhosis-negative patients: 0.45 COI, 
IQR: 0.33–0.62; p = 0.015). 
DISCUSSION
To date, there are a few studies examining the role 
of WFA+-M2BP in predicting the development of HCC 
in CHB patients [11, 12, 17]. However, these studies 
recruited a heterogeneous group of patients who were both 
treatment-naïve and treatment-experienced. For studies 
with treatment-experienced patients using either interferon 
or NA therapy, the major confounding factor, namely the 
DNA levels, varied. 
To our knowledge, this is the first study to 
investigate the association between WFA+-M2BP and 
Figure 1: Pre-treatment and post-treatment WFA+-M2BP levels between the HCC and control groups. Abbreviations: 
HCC, hepatoceullar carcinoma 
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Table 2: Demographics of 114 CHB carriers stratified according to cirrhosis status
Cirrhosis-positive  
(n = 68)
Cirrhosis-negative 
(n = 46)
HCC 
(n = 34)
Non-HCC 
 (n = 34) p value
HCC  
(n = 23)
Non-HCC 
(n = 23) p value 
Age#, years 61.1(57.7–62.9)
62.4 
(57.9–62.2) 0.797
62.0
(54.2–66.7)
60.7
(53.2–68.3) 0.974
Male#, n (%) 20
(87.0%)
20
(87.0%)
1.00
28 
(82.4%)
28 
(82.4%) n.a.
HBeAg-ve#, n (%) 22(95.7%)
22
(95.7%) 1.00
34 
(100%)
34 
(100%)
n.a.
Albumin, g/L 43
(40–47)
44
(42–46) 0.309
45 
(42–46)
43 
(41–46) 0.458
Bilirubin, umol/L 11 (7–17)
11
(9–17) 0.927
12 
(9–17)
10 
(8–15) 0.183
ALT, U/L 34 (24–43)
23
(20–29)
0.002
25
(17–32)
21
(20–28)
0.692
Platelet, x 10 ^9/L 132 
(91–170)
153
(125–192) 0.102
188 
(166–215)
208 
(174–259) 0.199
INR 1.1 
(1.0–1.1) 
1.1
(1.0–1.1)
0.385
1.1 
(1.0–1.1)
1.0  
(1.0–1.0)
0.166
AFP, ng/mL 11(5–27)
3
(2–4) < 0.001
14 
(7–53)
3 
(2–3) < 0.001
Undetectable DNA#, n 
(%)
34
(100%)
34
(100%)
1.00
23
(100%)
23
(100%)
n.a.
Duration of therapy#, 
years
3.4
(2.0–5.1)
3.7
(2.1–5.1) 0.652
3.2 
(2.1–4.7)
3.4 
(2.5–5.0)
0.582
Continuous variables expressed as median (interquartile range).
CHB, chronic hepatitis B virus; HCC, hepatocellular carcinoma; ALT, alanine aminotransferase; INR, international 
normalised ratio; AFP, alpha-fetal protein.
# Matched variables.
n.a., p-value not applicable as these were matched  categorical variable.
Table 3: Different NA therapies in HCC and control groups
HCC
(n = 57)
Non-HCC
(n = 57)
Entecavir 38(66.7%)
50
(87.7%)
Lamivudine 9(15.8%)
3
(5.3%)
Telbivudine 1(1.8%)
1
(1.8%)
Adefovir 6
(10.5%)
2
(3.5%)
Tenofovir 3(5.3%)
1
(1.8%)
NA, nucleos(t)ide analogue; HCC, hepatocellular carcinoma.
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HCC development in a strictly defined cohort of patients 
with profound viral suppression under NA therapy. This 
unique group of patients is increasingly common to be 
encountered in daily clinical practice due to the widespread 
use of potent antiviral therapy, yet the risk factors for HCC 
development have still not been well investigated
We found that there was a significant difference in 
the median levels of pre-treatment WFA+-M2BP between 
HCC and control groups (0.67 and 0.41 COI, respectively), 
suggesting that pre-treatment WFA+-M2BP is one of the 
risk factors for HCC development in patients who are 
receiving NA therapy. Furthermore, on subgroup analysis, 
Figure 2: AUROC of pre-treatment WFA+-M2BP for HCC prediction in CHB patients. (A) CHB patients (whole cohort); 
(B) CHB patients with cirrhosis; (C) CHB patients without cirrhosis; Abbreviations: AUROC, area under receiveroperating curve; WFA+-
M2BP, Wisteria floribunda agglutinin-positive human Mac-2 binding protein; HCC, hepatocellular carcinoma; CHB, chronic hepatitis B.
Table 4: Predictive accuracies of HCC for different cutoff values of pre-treatment WFA+-M2BP 
in different groups of patients
Whole cohort
(WFA+-M2BP 
≥ 0.69 COI)
Cirrhosis-positive
(WFA+-M2BP 
≥ 0.69 COI)
Cirrhosis-negative
(WFA+-M2BP 
≥ 0.34 COI)
Sensitivity 49% 59% 83%
Specificity 84% 76% 61%
Positive-predictive value 76% 71% 68%
Negative-predictive value 62% 65% 78%
HCC, hepatocellular carcinoma; WFA+-M2BP, Wisteria floribunda agglutinin positive Mac-2 binding protein.
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we found that this finding was consistent regardless of the 
cirrhosis status. This observation can be partially explained 
by the fact that WFA+-M2BP was found to correlate with 
the severity of fibrosis among patients without cirrhosis 
[11, 12, 14]. The observation that only pre-treatment but not 
post-treatment WFA+-M2BP was different between the two 
groups suggests that WFA+-M2BP is more suitable to be a 
predictive marker of HCC instead of a diagnostic marker.
For the whole study cohort, the OR of HCC 
development with pre-treatment WFA+-M2BP level ≥ 0.69 
COI was 4.80 (95% CI: 1.83–12.58). With this cutoff 
value, this test has a reasonable performance with an 
AUROC of 0.70. Among patients without cirrhosis, with 
a cutoff value of 0.34, the AUROC to predict HCC was 
even higher (0.77) with a high sensitivity of 83%. 
The findings of the present study have significant 
clinical implications as WFA+-M2BP may help to further 
stratify the risk of HCC development in patients with 
cirrhosis as well as those without cirrhosis. This in turn 
will help to streamline the management plan in terms of 
follow-up interval and HCC surveillance. 
The proportion of CHB patients receiving NA therapy 
has been increasing. For instance, in a nationwide cohort 
study of Taiwan, it was found that > 40% of CHB patients 
were NA-experienced [20]. With potent nucleos(t)ide 
analogues (entecavir and tenofovir), the majority of CHB 
patients are able to achieve profound viral suppression with 
undetectable serum HBV DNA level. However, NA therapy 
can only reduce but not eliminate the risk of HCC [19]. 
As yet, there are no satisfactory tests to predict HCC in 
patients under treatment [18], highlighting the importance 
of exploring alternative predictive factors. Therefore, 
further follow-up studies to improve the predictive power 
of WFA+-M2BP by adding in other already identified risk 
factors for the development of HCC, e.g. age, gender and 
other viral markers, HBsAg and hepatitis B core-related 
antigen (HBcrAg), are highly recommended [21, 22]. 
Another interesting observation in the present study 
about the characteristics of WFA+-M2BP is that the levels 
and cut-off values tend to be lower in CHB patients than 
in patients with other liver diseases (including HCV, AIH, 
PBC, non-alcoholic fatty liver disease) [14, 15, 23–25]. 
In a large study investigating the role of WFA+-M2BP 
in 1,323 CHB patients (a heterogeneous group of CHB 
patients who were either treatment-naïve or treatment-
experienced), the median WFA+-M2BP level was 0.61 
(IQR: 0.40–1.01) [17]. While the optimal cutoff value for 
predicting HCC in treatment-experienced chronic HCV 
patients was 2.2 COI as determined by a previous study 
[14], the cutoff value was much lower as defined in our 
study (0.69 COI). This was consistent with the finding 
from another study on CHB patients [12], in which the 
optimal cutoff value for HCC prediction was 0.71 COI. 
In this study by Ichikawa et al, although the median levels 
of baseline ALT were raised (66.5 IU/L; IQR: 40–132), 
the median levels of baseline WFA+-M2BP remained to be 
low (0.97 COI). One postulation is that it may be related 
to gender variability, in which women were found to have 
higher WFA+-M2BP levels than men [15, 26]. As female 
accounted for more than 80% of the cohort in previous 
studies on AIH and PBC, while the majority of patients 
in our study and another study were male [12], this may 
partly explain the lower WFA+-M2BP level in our study. 
There are several limitations of our study. Firstly, the 
role of WFA+-M2BP in predicting HCC is best assessed by a 
prospective cohort study, instead of the retrospective nature 
of the present study, which precludes the determination of 
hazard ratio of this marker. Secondly, the relatively small 
sample size (due to the stringent matching criteria with 6 
variables) may render the study less powerful for detecting 
more significant differences, especially among patients 
with cirrhosis. Further studies will be needed to determine 
more precise cut-off value for the prediction of HCC 
development in CHB patients. However, these stringent 
criteria helped to minimize the selection biases inherent 
to a retrospective study, and to prove the association of 
HCC development and WFA+-M2BP more convincingly. 
Thirdly, not all patients had transient elastography or liver 
biopsies done, which precluded stratified analysis according 
to different fibrosis stages. Nonetheless, the proportions of 
patients with significant fibrosis (as defined by a FIB-4 
value of more than 1.45) both before and after treatment 
were comparable between the HCC and control groups. 
This partly addressed the concern that the severity of 
fibrosis could be different between the two groups despite 
the matching of their cirrhosis status.  
In conclusion, the present study showed that 
WFA+-M2BP could be a novel risk marker to predict 
HCC development in CHB patients with profound viral 
suppression under NA therapy. WFA+-M2BP measurement 
may serve as a useful strategy for risk stratification in 
terms of follow-up interval and HCC surveillance. Future 
prospective researches with larger sample size on the role 
of WFA+-M2BP specifically for treatment-experienced 
subjects are warranted.
MATERIALS AND METHODS 
Patient recruitment 
Patients were recruited from the Hepatology Clinic, 
Department of Medicine, The University of Hong Kong, 
Queen Mary Hospital, Hong Kong, from January 2007 to 
November 2014. 
We recruited all CHB patients who developed 
HCC despite achieving profound viral suppression (i.e. 
undetectable serum HBV DNA levels by the Cobas 
Tagman assay) under NA therapy for at least 1 year before 
the diagnosis of HCC. Other inclusion criteria included age 
≥ 18 years, no significant alcohol consumption (> 30 gram 
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and > 20 gram per day for men and women, respectively), 
no coexisting liver diseases like HCV infection, primary 
biliary cholangitis (PBC), autoimmune hepatitis (AIH) and 
Wilson’s disease, as well as no previous history of HCC. 
Seventy-six HCC cases were identified. After 
excluding cases who did not have available serum samples 
for measurement of WFA+-M2BP level (n = 19), 57 
patients with HCC were recruited into the present study. 
Control subjects were NA-treated CHB patients 
without HCC development. These control patients were 
matched with the HCC patients by age, gender, hepatitis e 
antigen (HBeAg) status, cirrhosis status (definition mentioned 
below) and duration of NA therapy in a 1:1 ratio. Figure 3 
shows the flow diagram of the patient recruitment process. 
Both pre-treatment (within 1 year before 
commencement of NA therapy) and post-treatment levels 
(at the time of HCC diagnosis for the HCC group and at the 
time when the control group had the same matched duration 
of therapy) of serum WFA+-M2BP were determined and 
compared between the two groups. Moreover, to study the 
association between WFA+-M2BP and cirrhosis, the pre-
treatment and post-treatment levels of serum WFA+-M2BP 
were compared between the controls with and without 
cirrhosis. 
The study protocol was approved by the Institutional 
Review Board, the University of Hong Kong and West 
Cluster of Hospital Authority, Hong Kong. 
Surveillance and diagnosis of HCC
We followed up the patients every 3 to 6 months 
with regular blood tests, which included HBeAg/anti-
HBe, albumin, bilirubin, alanine aminotransferase (ALT), 
platelet count, international normalized ratio (INR), 
alpha-fetoprotein (AFP) and serum HBV DNA level. In 
accordance with the standard guidelines, patients were 
advised for ultrasonography of the hepatobiliary system 
every 6 months [27]. 
HCC was diagnosed by either histology or typical 
radiological features (arterial enhancement and venous 
wash-out by triphasic computed tomography [CT] scan 
or contrast magnetic resonance imaging [MRI]). Cirrhosis 
was diagnosed by one of the following 3 modalities: (1) 
imaging (USG/CT/MRI showing small liver, liver with 
an irregular outline, or features of portal hypertension 
including splenomegaly, varices and ascites), (2) 
transient elastography measured with a liver stiffness 
measurement of > 12 kilopascals [7], or (3) clinical 
features (thrombocytopenia, coagulopathy, ascites, hepatic 
hydrothorax, varices and hepatic encephalopathy). 
Diagnosis of significant fibrosis 
The presence of significant fibrosis was defined by 
a Fibrosis 4 index (FIB-4) value of more than 1.45 [28]. 
Figure 3: Flow chart of disposition of patients. Abbreviations: HCC, hepatocellular carcinoma; HBsAg, hepatitis B surface antigen; 
WFA+-M2BP, Wisteria floribunda agglutinin-positive human Mac-2 binding protein; HBeAg, hepatitis B e antigen.
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At present, FIB-4 and aminostransferase-to-platelet ratio 
index (APRI) are the two widely studied non-invasive 
fibrosis markers based on readily available parameters 
(i.e. age, aminotransferase levels and platelet count). As 
a recent meta-analysis showed that FIB-4 outperformed 
APRI in detecting fibrosis, FIB-4 was used a surrogate 
marker for detecting significant fibrosis in our study [28].
Treatment
The indications of commencing NA therapy 
included [1] a persistently elevated ALT level with high 
serum HBV DNA level (≥ 2,000 IU/mL), and/or [2] 
cirrhosis with detectable serum HBV DNA [29]. 
Quantification of serum HBV DNA and WFA+-
M2BP levels
Blood tests for HBV DNA and WFA+-M2BP 
levels were performed in serum stored at –20°C before 
treatment and during follow-up. Serum HBV DNA 
level was measured by the Cobas Taqman HBV Test 
(Roche Diagnostics, Branchburg, NJ, USA) with a lower 
limit of detection of 20 IU/mL. Serum WFA+-M2BP 
level was measured by HISCL M2BPGi reagent kit 
(Sysmex Corporation, Hyogo, Japan) on an automatic 
immunoanalyzer HISCL-800 (Sysmex Corporation, 
Hyogo, Japan) at Health-Tech Medical Laboratory Ltd in 
Hong Kong [8], and the measurement value was expressed 
as cutoff index (COI) by using the following equation: 
Cutoff index (COI) = ([WFA+-M2BP]sample−
[WFA+-M2BP]NC)/([WFA+-M2BP]PC−[WFA+-M2BP]
NC). [WFA+-M2BP]sample refers to the WFA+-M2BP 
level of samples from recruited patients. NC and PC stand 
for negative control and positive control, respectively. The 
WFA+-M2BP level of PC from a calibration solution is 
standardized with a COI value of 1.0 [9].
Statistical analyses 
All statistical analyses were performed using R 
version 3.2.3 (R Foundation for Statistical Computing) 
statistical software. Continuous variables were expressed 
as median and interquartile range (IQR). Spearman’s 
bivariate correlation was used to test the correlation between 
continuous variables. For comparisons of continuous 
variables between two groups, the Mann-Whitney U-test 
was used. For comparisons of categorical variables, the Chi-
square test or Fisher’s exact test were used when appropriate. 
The receiver operating curve was generated by plotting the 
‘sensitivity’ against ‘1 - specificity’ at different values. The 
performance of WFA+-M2BP was measured in term of area 
under receiver operating curve (AUROC). By maximizing 
the Youden’s index (i.e. sensitivity + specificity -1) from 
the AUROC analysis, optimal cutoff values for predicting 
HCC development were derived. In turn, the sensitivity, 
specificity, positive predictive value (PPV) and negative 
predictive value (NPV) were determined. The odds ratio 
(OR) of HCC development for different variables was 
derived from conditional logistic regression as the cases and 
controls were matched samples. Statistical significance was 
defined by a two-sided p-value of < 0.05. 
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